Eligibility criteria+3,738 characters
Inclusion Criteria for Screening:
Women or men aged 18 years and older.
Previous diagnosis o [...] with or without progesterone receptor positivity.
Patients who arewith PR positive but ER-negative are not eligible.
Participants [...] ER2- breast cancer at least five years ago and no more than 1520 years ago and must have completed adjuvant endocrine therapy.
Participants must be off endocrine therapy for at least sixfour monthsweeks prior to screening.
Exclusion Criteria for Screening:
Known current metastatic disease.
Known contraindication t [...] art receiving therapy on another therapeutic clinical trial.
C [...]
Secondary endpoints6 to 7 entries
Patient-Reported Outcomes, Fear of Recurrence and Anxiety Levels During Elacestrant Treatment
Diet and Physical Activity Levels in Breast Cancer Patients
Study description+163 characters
[...] be ctDNA tested every six months and monitored for one year.
If andpatients willremain bectDNA allowedpositive at the completion of 12 months of study treatment, since they remain at increased risk of recurrence, they can choose to continue on elacestrant for an additional year12 months for a maximum of 24 months, they may also resume standard endocrine therapy, or continue with standard of care surveillance during follow up.
Study sitescontacts updated at 1 of 1 site
Study title-38 characters
ctDNACirculating GuidedTumor Adjuvant Treatment With Elacestrant: TBCRC-068DNA